Product Name: APITD1 Antibody
Species Reactivity: Human, Mouse
Tested Applications: IHC-P, WB
Applications: For WB starting dilution is: 1:1000For IHC-P starting dilution is: 1:50~100For FACS starting dilution is: 1:10~50
User Note: Optimal dilutions for each application to be determined by the researcher.
Predicted Molecular Weight: 16 kDa
Immunogen: This APITD1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 48-74 amino acids from the Central region of human APITD1.
Host Species: Rabbit
Purification: This antibody is purified through a protein A column, followed by peptide affinity purification.
Physical State: Liquid
CAS NO.: 163769-88-8
Product: YM-90709
Buffer: Supplied in PBS with 0.09% (W/V) sodium azide.
Concentration: 0.5 mg/ml
Storage Conditions: Store at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Clonality: Polyclonal
Conjugate: Unconjugated
Alternate Names: Centromere protein S, CENP-S, Apoptosis-inducing TAF9-like domain-containing protein 1, FANCM-interacting histone fold protein 1, Fanconi anemia-associated polypeptide of 16 kDa, APITD1, CENPS, FAAP16, MHF1
Accession NO.: Q8N2Z9
Protein Ino: 74759833
Official Symbol: APITD1
Geneid: 100526739, 378708
Background: APITD1 was identified in the neuroblastoma tumour suppressor candidate region on chromosome 1p36. It contains a TFIID-31 domain, similar to that found in TATA box-binding protein-associated factor, TAF(II)31, which is required for p53-mediated transcription activation. This gene was expressed at very low levels in neuroblastoma tumours, and was shown to reduce cell growth in neuroblastoma cells, suggesting that it may have a role in a cell death pathway.
PubMed ID:http://aac.asm.org/content/53/2/421.abstract
